Article Text

Download PDFPDF

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
  1. Berna C Özdemir1,2
  1. 1Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
  2. 2International Cancer Prevention Institute, Lausanne, Switzerland
  1. Correspondence to Dr Berna C Özdemir; berna.oezdemir{at}


Despite a significant amount of data on incidence and therapy of immune-related adverse events affecting virtually all organ systems, the potential impact of immune checkpoint inhibitors (ICIs) on gonadal function has not been sufficiently studied. The limited evidence available suggests that ICI-related primary hypogonadism due to orchitis as well as secondary hypogonadism due to hypophysitis are a potential risk for infertility. A systematic investigation of gonadal function under ICIs is warranted given the increasing application of ICIs in the adjuvant setting, among young adults and children and the possible influence of sex hormone levels on the efficacy and toxicity of ICIs.

  • immunotherapy

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Since the approval of ipilimumab in 2011, immune checkpoint inhibitors (ICIs) have significantly improved the treatment landscape of multiple cancer types. According to a recent analysis, approximately 43% of patients with cancer in the USA are eligible for ICIs, of whom 12% are estimated to respond.1 Nearly all patients undergoing ICIs will experience at least one type of immune-related adverse event (irAE), which can occur at any moment even months or years after therapy discontinuation. Moreover, these irAEs can affect any organ and be severe depending on the therapy regimen and underlying health condition of the patient, with 10%–30% of cases categorized as grades 3–5.2 Endocrine toxicities are among the most common irAEs and, in contrast to other irAEs, tend to be irreversible and require life-long hormonal substitution. The most frequent endocrine complications are thyroid dysfunction (30%), hypophysitis (5.6%–11%), type I diabetes (0.2%–2%), and adrenal insufficiency (0.7%), although rare cases of hypoparathyroidism have also been described.3 Yet, surprisingly little is known about the potential impact of ICIs on gonadal function. A recent analysis of VigiBase, the WHO global database of individual case safety reports between 2011 and 2019, found a significant, disproportionately increased risk of hypogonadism for ICIs. Of the 13 reported cases of hypogonadism, 5 were classified as secondary and 1 as primary hypogonadism.4 A similar analysis of the French Pharmacovigilance database identified 94 cases of ICI-related hypophysitis, of whom 8% showed panhypopituitarism.5 Although panhypopituitarism can cause secondary hypogonadism, the levels of the pituitary gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were rarely assessed and supplementation with gonadotropic hormones was mostly lacking.5

In a retrospective single-center review of 154 patients treated with ipilimumab, hypophysitis was found in 17 (11%) of the patients and the anterior portion of the pituitary gland, responsible for gonadotropin secretion, was affected in all cases. The levels of LH, FSH and testosterone were measured in 11 patients and were low, estradiol was not measured in the two female patients who were postmenopausal. The gonadal function normalized in two patients.6 Another center also reported an 11% incidence of hypophysitis under ipilimumab. The majority of the 15 affected patients presented gonadotropin deficiency (80%, n=12) that persisted in 16% of the cases at almost 3 years of follow-up.7

Even in the absence of hypophysitis, low total testosterone levels were reported in a retrospective single-center review of patients with melanoma. However, the actual incidence and extent of ICI-related hypogonadism remains unknown because measurements were not repeated nor performed systematically in all analyzed patients.8

In addition to this central hypogonadism, ICI-induced inflammation of the gonads can be associated with impaired gonadal function, possibly leading to hypogonadism and infertility. Two cases have been reported of patients with metastatic melanoma who developed acute painful swelling of the testicles which turned out to be bilateral orchitis9 and epididymo-orchitis10 under ipilimumab-nivolumab and pembrolizumab, respectively. While hormone measurements in the first case showed transient primary hypogonadism with low testosterone and high LH levels which recovered spontaneously, no hormone levels were measured in the second case which resolved after treatment with high-dose steroids. An analysis of 13 metastatic melanoma patients with testicular autopsy tissue samples showed that six of the seven men (86%) who had received ICIs had impaired spermatogenesis compared with age-matched patients who were treatment naïve (n=6).11 No data on potential effects on female fertility are currently available.

This lack of data is astonishing given the vast number of clinical trials performed over the last decade. For instance, none of the pivotal trials leading to Food and Drug Administration (FDA approval of ICIs in the different indications has provided information regarding fertility, menopause status, sex hormone levels, or sexual health-related quality of life. However, the assessment of gonadal function in reproductive-age men and women undergoing ICIs cannot be deferred any longer. ICIs are increasingly applied in the curative setting as adjuvant therapy where the risk of ICI-related hypogonadism, premature menopause or infertility, and their long-term consequences need to be balanced against the reduction of absolute risk of disease recurrence and discussed with the patient as it might affect the acceptance of such prophylactic therapies. In addition, the cancer incidence in young adults is increasing, with currently about 5% of all cancers being diagnosed in patients 20–39 years of age. It is therefore likely that in the future more reproductive-age men and women will be exposed to ICIs and need to be informed about the potential for gonadal toxicity.12 Similarly, multiple clinical trials are testing ICIs in pediatric patients and ICIs are already approved for several indications in this population. The current state of evidence does not provide any meaningful conclusions that can be used to counsel patients and their families regarding the risk of hypogonadism and its potential effects on the children’s physical and mental development.

Even in the metastatic setting, patients need to be informed about potential hypogonadism or infertility considering that a subpopulation of patients will achieve durable, complete remission and might consider having children. More recently, ICIs have been incorporated into the standard of care in women with advanced breast cancer. Indefinite ovarian function suppression is a cornerstone of the management of premenopausal women with endocrine responsive advanced breast cancer. As such, it is important to determine whether ICIs affect ovarian function and future fertility in order to provide appropriate guidance regarding fertility preservation and to adapt treatment schemes. Additionally, whether the occurrence of ICI-related hypogonadism has a prognostic and predictive value also needs to be determined.

Another important issue to consider is the teratogenic potential of ICIs. The PD-1/PD-L1 and the CTLA4/CD80/CD86 pathway are essential to induce maternal tolerance and prevent rejection of the semi-allogenic fetus. In pregnant mice, treatment with anti-PD-L1 antibodies dramatically increases the rate of abortion (86%) compared with spontaneous abortion (18%), by depleting regulatory T cells (Tregs).13 Likewise, in pregnant cynomolgus monkeys which received nivolumab from the onset of organogenesis through delivery, increased abortion and premature neonatal death were observed.13 Therefore, the FDA advises women of childbearing age to use effective contraception during treatment with anti-CTLA4 and anti-PD-1 anti-PD-L1 antibodies for at least 3–5 months, respectively, after the last dose.14

Currently, we have only limited knowledge on the effect of checkpoint inhibitors on the outcome of pregnant patients with cancer and their offspring. Three cases of ICI therapy in pregnant women with metastatic melanoma,15–17 as well as two cases18 19 of successful pregnancy that was conceived during treatment with ICIs with anti-PD1 alone or in combination with anti-CTLA4, were reported. None of the infants showed any developmental anomalies, except for congenital hypothyroidism detected in one newborn, possibly representing a fetal irAE from maternal anti-PD1 exposure.18

Given that melanoma is the most common malignancy during pregnancy and approximately one-third of all women diagnosed with melanoma who will be treated with ICI are of childbearing age,20 investigation of the safety of ICIs in an international registry prospectively collecting data on pregnant patients with cancer treated with ICI could be of great clinical value.20

The perturbation of sex hormone levels at the pituitary or gonadal level is not solely an issue of fertility and sexual health but might also affect efficacy and toxicity of ICIs. It has been reported21 that men derive a greater benefit from ICIs compared with women, which could be attributable to many biological factors including differences in the host hormonal milieu that affect response to ICIs.22 A systematic investigation of the potential impact of ICIs on gonadal function could be done by retrospectively analyzing sex hormone levels in serum from patients included in randomized clinical trials on adjuvant ICIs. Additionally, there are numerous clinical trials testing neoadjuvant ICIs in locally advanced tumors without prior anticancer therapy, a potential gonadotoxic effect of ICIs could be prospectively determined in these patients. Also, pooled analysis of real world data from large centers applying ICIs could provide important information regarding the clinical relevance of ICI-related hypogonadism. For a proper estimation of its true incidence, systematic collection of a minimal dataset including menopause status and measurement of LH, FSH and estradiol or testosterone levels, respectively, for all patients before starting ICIs and at occurrence of an irAE and every 3 months during therapy as well as during follow-up should be done. In particular, patients presenting with hypophysitis need long-term monitoring for gonadotropin deficiency in order to map the risk of persistent hypogonadism. Considering that patients with cancer rarely report spontaneously on their sexual health, physicians should regularly inquire on signs of hypogonadism such as erectile dysfunction, decreased libido, menstrual irregularities, vaginal dryness and hot flushes in order to detect patients at risk.

Confirming or excluding a potential effect of ICIs on gonadal function will not only help improve the counseling and treatment of patients with cancer in their reproductive years and the quality of life of cancer survivors but also contribute to a better understanding of the influence of sex hormones on efficacy and toxicity of these therapies.


I would like to thank Professor Gian-Paolo Dotto and Ms Cristina Espinosa da Silva for their critical reviews and useful comments.



  • Contributors I am the sole author of this manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.